Liver Biopsy Market Trends and Overview

The Liver Biopsy Market was valued at USD 5,160 million in 2022 and is projected to reach USD 8,539 million by 2030, exhibiting a robust compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2030.

Liver biopsy is a diagnostic procedure that involves the extraction of a small sample of liver tissue for examination. It plays a crucial role in the diagnosis and monitoring of various liver diseases, including hepatitis, cirrhosis, and liver cancer. The increasing prevalence of these conditions, coupled with the growing awareness about the importance of early detection and treatment, is driving the demand for liver biopsy procedures.

Furthermore, advancements in medical technology have led to the development of minimally invasive techniques, such as ultrasound-guided and laparoscopic liver biopsies, which offer several advantages over traditional open biopsies. These techniques not only reduce patient discomfort and recovery time but also provide more accurate and reliable results.

The rising adoption of these minimally invasive procedures, along with the growing geriatric population and the increasing incidence of liver diseases worldwide, are key factors contributing to the market's growth. Additionally, the expanding healthcare infrastructure and the availability of skilled healthcare professionals further support the market's expansion.

Geographically, North America currently dominates the liver biopsy market, owing to the presence of well-established healthcare facilities, high healthcare expenditure, and a large patient pool. However, the Asia Pacific region is expected to witness significant growth during the forecast period, driven by the rising healthcare investments, improving healthcare infrastructure, and increasing awareness about liver diseases.

In conclusion, the liver biopsy market is poised for substantial growth in the coming years, driven by the increasing prevalence of liver diseases, advancements in medical technology, and expanding healthcare infrastructure. As healthcare providers and patients recognize the importance of early diagnosis and treatment, the demand for liver biopsy procedures is expected to soar, creating lucrative opportunities for market players.

Get Free Sample Report @


By Procedure

  • Percutaneous Biopsy
  • Trans jugular Biopsy
  • Laparoscopic Biopsy
  • Robotic Biopsy

By End-User

  • Hospitals
  • Clinics and Ambulatory Surgical Centers
  • Research and Academic Institutes

By Application

  • Liver Cirrhosis
  • Hepatitis
  • Liver Cancer
  • Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
  • Other Liver Diseases

By Technology

  • Conventional Biopsy Needles:
  • Vacuum-Assisted Biopsy Systems
  • Image-Guided Biopsy
  • Other Emerging Technologies

Major Players Listed in the Report are as Follows:

Becton, Dickinson and Company (BD), Cook Medical, Medtronic placebos Scientific Corporation, Olympus Corporation, Veran Medical Technologies, Angiotech Pharmaceuticals, TSK Laboratory, Cardinal Health, SOMATEX Medical Technologies, Argon Medical Devices, Med axiom Corporation, Merit Medical Systems, Path Group & Other Players.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),